GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects ... with Pfizer claiming commercial rights to the shingles shot in all territories other than BioNTech's home market ...

When I pre-chart on patients coming to see me for their Medicare annual wellness visits, or for their annual physical that's ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

Our commercial success with HEPLISAV-B has transformed Dynavax ... offer meaningful value for both patients and shareholders alike. Moving to our Z-1018 shingles vaccine program. We are actively ...

Nova Scotia's Progressive Conservatives promised on Tuesday to introduce a universal shingles vaccine program for people 65 and older if re-elected Nov. 26, the latest in a series of targeted ...

Finally, it’s too late for your mother, but older people who have not had the newer two-dose shingles vaccine (Shingrix) should get it, even if they had the old one-dose vaccine (Zostavax ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected ...